Drugs / AAV2hAQP1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04043104 | Jun 2019 → Mar 2023 | head and neck cancer | MeiraGTx UK II Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02446249 | May 2015 → Jul 2026 overdue | head and neck squamous cell carcinoma, radiation-induced disorder, salivary gland disorder | MeiraGTx, LLC | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06544798 | Aug 2024 → Feb 2032 expected | — | MeiraGTx, LLC | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05926765 | Jun 2023 → Dec 2026 expected | — | MeiraGTx, LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV2hAQP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04043104 ↗ |
| Action | Restore | “restoring salivary flow to IR-damaged salivary glands” NCT02446249 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV2hAQP1 gene therapy” NCT02446249 ↗ |
| Route | Other | “It will be slowly pushed into the parotid gland through the parotid duct” NCT02446249 ↗ |